Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end
FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026
Faeth Therapeutics (NASDAQ:FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones.
"Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Ph